DoubleVerify Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DV research report →
Range $13.6 – $13.6
Price Chart
About the company
DoubleVerify Holdings, Inc. offers a comprehensive software platform designed for measuring, analyzing, and providing data insights for digital media, serving clients both domestically and across global markets. Through its various offerings, the company equips advertisers with impartial data analytics, empowering them to significantly enhance the impact, integrity, and financial returns of their online advertising campaigns.
- CEO
- Mark S. Zagorski
- IPO
- 2021
- Employees
- 1,231
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on DV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.12B
- P/E
- 14.64
- Fwd P/E
- 33.77
- PEG
- 0.76
- P/S
- 1.92
- P/B
- 2.76
- EV/EBITDA
- 9.15
- Div Yield
- 0.00%
- Gross Margin
- 57.39%
- Op Margin
- 19.86%
- Net Margin
- 12.84%
- ROE
- 18.33%
- ROIC
- 13.53%
Latest fiscal year · YoY change
- Revenue
- $748.29M+13.9%
- Gross Profit
- $614.79M+13.8%
- Op Income
- $79.20M
- Net Income
- $50.65M-9.9%
- EPS
- $0.31-6.1%
- OCF Growth
- +32.3%
- FCF Growth
- +30.3%
- 52W High
- $13.65
- 52W Low
- $8.60
- 50D MA
- $13.51
- 200D MA
- $11.53
- Beta
- 0.94
- RSI (14)
- 58
- Avg Volume
- 2.62M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Covista delivered a strong first quarter beat on revenue, EBITDA, and EPS, raised full-year guidance, and reiterated confidence in its scale-and-capacity growth strategy despite some segment-level timing and investment pressures.· October 29, 2026
- Revenue rose 10.7% to $511.5 million; adjusted EBITDA rose 17.1% to $131.2 million; adjusted EPS rose 25.1% to $2.19.
- Total enrollment increased 7.6% and the company said it has now grown total enrollment for 13 consecutive quarters.
- Management raised fiscal 27 guidance for revenue to $2.06 billion-$2.095 billion and adjusted EPS to $9.00-$9.20.
- Capital returns remained aggressive: Covista repurchased $84 million of stock in the quarter and ended with $222 million in cash and net leverage of 0.5x.
- Chamberlain growth was softer than expected at 1.3% enrollment growth, but management expects improvement as new seats, partnerships, and pricing actions flow through.
First-quarter revenue increased 10.7% to $511.5 million. Adjusted EBITDA was $131.2 million, up 17.1% year over year, with adjusted EBITDA margin of 25.6%, up 1.4 percentage points. Adjusted net income rose 16.8% to $75.8 million and adjusted EPS was $2.19, up 25.1%. By segment, Chamberlain revenue increased 7.4% to $192.4 million and adjusted EBITDA rose 7.1% to $37.6 million; Walden revenue increased 14.1% to $216.7 million and adjusted EBITDA rose 16.1% to $71.9 million; and medical/veterinary revenue increased 10% to $102.5 million and adjusted EBITDA rose 27.9% to $27.4 million. Free cash flow over the trailing 12 months was $355 million, cash and cash equivalents were $222 million, and net leverage was 0.5x. Fiscal 27 guidance was raised to revenue of $2.06 billion-$2.095 billion and adjusted EPS of $9.00-$9.20. Management also said it continues to expect 0 to 0.5 percentage points of EBITDA margin expansion for the full year, capital expenditures above fiscal 26, and a higher effective tax rate versus fiscal 26.
Stephen W. Beard framed the quarter as evidence that Covista is executing ahead of plan and that its 'purpose at scale' strategy is working. He emphasized durable demand in health care, the capacity constraints in the market, and the company’s ability to fund growth from operating cash while still returning capital. His tone was confident and strategic, repeatedly stressing that the company is building new campuses, programs, partnerships, and AI-enabled technology to widen its moat over the next three years.
Robert J. Phelan highlighted the core financial story: strong top-line growth, operating leverage, and cash generation. He cited $511.5 million of revenue, $131.2 million of adjusted EBITDA, 25.6% adjusted EBITDA margin, $355 million of trailing 12-month free cash flow, $222 million of cash, and 0.5x net leverage. He also noted debt and capital allocation actions, including repricing the $510 million term loan B to SOFR plus 2%, repurchasing about 660 thousand shares for $84 million at an average price of $127.63, and leaving $578 million under the authorization. On guidance, he raised fiscal 27 revenue and EPS while pointing to new campus startup costs, the Walden calendar shift, and a higher tax rate as reasons for prudence.
Analysts focused on whether recent loan-policy changes or confusion around nursing classifications affected enrollment, whether any expenses were shifted between quarters, and how to think about margin cadence and revenue-per-student trends. Management said there was no impact from the nursing classification issue and that the main effects from loan changes were in medical and veterinary, where some demand was pulled forward and some families remain hesitant until they understand financing options. On expenses, management said there were no costs shifted out of the first quarter; instead, some additional investments were made in Q1 and revenue outperformance drove the beat. They also explained that Chamberlain’s enrollment growth should improve later in the year, that Walden’s calendar shift will pressure Q2 comparisons but benefit Q3, and that AI search has not yet created meaningful headwinds in inquiry, application, or enrollment.
The call showed strong demand across the portfolio, with double-digit growth at Walden and medical/veterinary and continued growth at Chamberlain. Management said the company is ahead of its fiscal 27 plan, has durable cash generation, and can keep investing in capacity and technology while still buying back stock. They also expressed confidence that partnerships with health systems, new campuses, and better AI-search visibility can extend growth.
Chamberlain’s total enrollment growth of 1.3% was below expectations, with management pointing to softer continuing-student retention and lingering weakness in RN-to-BSN. Guidance was raised only modestly relative to the quarter’s beat because management is watching new-campus startup costs, a higher tax rate, and a Walden calendar shift that will make Q2 comparisons weaker. There is also some uncertainty around loan-policy effects and the need to keep educating prospective students on financing options, especially in medical and veterinary.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.0%
- Shares Outstanding
- 156.21M
- Float Shares
- 135.88M
of shares held by institutions
331 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 22.71M | ▼ 441.55K |
| Providence Equity Partners L.L.C. | 18.34M | 0 |
| Vanguard Group Inc | 14.78M | ▲ 360.06K |
| Vanguard Portfolio Management LLC | 7.64M | ▼ 1.30M |
| Disciplined Growth Investors Inc /Mn | 7.06M | ▼ 2.63M |
| Vanguard Capital Management LLC | 5.94M | ▲ 28.97K |
| Dimensional Fund Advisors LP | 5.82M | ▲ 429.14K |
| State Street Corp | 5.47M | ▲ 89.99K |
| Geode Capital Management, LLC | 3.43M | ▼ 9.29K |
| Balyasny Asset Management L.P. | 3.37M | ▲ 3.34M |
| Aqr Capital Management LLC | 3.10M | ▼ 4.68M |
| Qube Research & Technologies Ltd | 2.62M | ▲ 1.93M |
Held by 417 ETFs
Biggest fund positions in DV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Noell Robert Davis | other | 40,658 |
| Oct 31, 26 | Mougis Steven John | other | 802 |
| Sep 30, 26 | Zagorski Mark | other | 13,476 |
| Sep 30, 26 | Zagorski Mark | other | 6,880 |
| Sep 30, 26 | Zagorski Mark | other | 13,476 |
| Sep 15, 26 | Mougis Steven John | other | 27,056 |
| Sep 15, 26 | Mougis Steven John | other | 1,143 |
| Sep 15, 26 | Mougis Steven John | other | 2,125 |
| Sep 15, 26 | Mougis Steven John | other | 584 |
| Sep 15, 26 | Mougis Steven John | other | 1,085 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DV coverage
Recent articles, reports, and earnings notes.
No research on DV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DV report →STUDY: From AI to In-Store, New Research Reveals How Consumers Research and Shop Across Channels
globenewswire.com · Nov 19
Here's What Key Metrics Tell Us About DoubleVerify (DV) Q3 Earnings
zacks.com · Oct 30
DoubleVerify Holdings (DV) Lags Q3 Earnings Estimates
zacks.com · Oct 30
DoubleVerify Stockholders Approve Merger Agreement at Special Meeting
marketbeat.com · Oct 30
DoubleVerify Reports Third Quarter 2026 Financial Results
globenewswire.com · Oct 30
DoubleVerify Holdings (DV) Earnings Expected to Grow: Should You Buy?
zacks.com · Oct 30
DV Research: 97% of Marketers Plan to Use AI, but Adoption Across Advertising Workflows Remains Uneven
globenewswire.com · Oct 29
Analyzing Palantir Technologies (NASDAQ:PLTR) and DoubleVerify (NYSE:DV)
defenseworld.net · Oct 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.